RARE · Ultragenyx Pharmaceutical Inc.
Market Cap
$1.51B
Shares
98.59M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-09-02 | — | |
| Investor Event Transcript | 2026-08-19 | 2026-09-30 | |
| 8-K | 2026-08-19 | — | |
| 8-K | 2026-08-11 | 2026-08-07 | |
| 10-Q | 2026-08-05 | 2026-06-30 | |
| 8-K | 2026-08-04 | — | |
| Investor Event Transcript | 2026-06-09 | 2026-06-30 | |
| 8-K | 2026-05-18 | 2026-05-14 | |
| 10-Q | 2026-05-06 | 2026-03-31 | |
| 8-K | 2026-05-05 | — | |
| 8-K | 2026-04-02 | — | |
| 8-K | 2026-03-30 | — | |
| DEF 14A | 2026-03-27 | 2026-05-14 | |
| 8-K | 2026-03-12 | — | |
| Investor Event Transcript | 2026-03-10 | 2026-03-31 | |
| 8-K | 2026-02-23 | — | |
| 10-K | 2026-02-18 | 2025-12-31 | |
| 8-K | 2026-02-12 | — | |
| 8-K | 2026-02-03 | — | |
| 8-K | 2026-01-30 | — | |
| 8-K | 2026-01-12 | — | |
| 8-K | 2025-12-30 | — | |
| 8-K | 2025-12-29 | — | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 8-K | 2025-11-04 | 2025-11-03 | |
| 8-K | 2025-10-30 | — | |
| 8-K | 2025-09-08 | — | |
| 8-K | 2025-08-18 | — | |
| 10-Q | 2025-08-06 | 2025-06-30 | |
| 8-K | 2025-08-05 | — | |
| 8-K | 2025-07-31 | — | |
| 8-K | 2025-07-11 | — | |
| 8-K | 2025-07-09 | — | |
| 8-K | 2025-06-27 | — | |
| 8-K | 2025-05-19 | 2025-05-15 | |
| 10-Q | 2025-05-07 | 2025-03-31 | |
| 8-K | 2025-05-06 | — | |
| DEF 14A | 2025-03-28 | 2025-05-15 | |
| 10-K | 2025-02-19 | 2024-12-31 | |
| 8-K | 2025-02-13 | — | |
| 8-K | 2025-01-13 | 2025-01-12 | |
| 8-K | 2024-12-19 | — | |
| 8-K | 2024-12-19 | — | |
| 8-K | 2024-11-12 | 2024-11-09 | |
| 10-Q | 2024-11-06 | 2024-09-30 | |
| 8-K | 2024-11-05 | — | |
| 8-K | 2024-10-07 | — | |
| 8-K | 2024-10-03 | — | |
| 10-Q | 2024-08-02 | 2024-06-30 | |
| 8-K | 2024-08-01 | — |
Showing 1–50 of 149 filings
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
220 filings
219 filers
Visit website
Investor relations